
(the "Company" and together with its subsidiaries the "Group" or "
Issue of Share Options and Director/PDMR Dealing
The EMI Plan is designed to enable the Company to recruit, retain, and reward key employees of the Group - in doing so aligning their interests with those of the Company's shareholders whilst enabling the Group to preserve cash resources ahead of the commercialisation of the Company's technology.
Performance Options
Of the Options, a total of 10,000,000 performance share options (the "Performance Options") have been awarded to executives and employees of the Company, including awards to certain of the Company's directors and PDMRs in the amounts set out below.
The award of Performance Options follows the
All vestings of the Performance Options are subject to the satisfaction of specific performance conditions prior to the vesting dates. The Performance Options are issued under the EMI plan and will be exercisable from vesting until the tenth anniversary of the date of grant.
Director/PDMR |
Number of Options |
Plan |
Exercise price |
|
3,000,000 |
EMI Plan |
5p |
|
1,600,000 |
EMI Plan |
5p |
|
1,500,000 |
EMI Plan |
5p |
Total |
6,100,000 |
- |
- |
Nominal Value Options
In addition to the Performance Option award, the Company has also issued a total of 520,000 nominal value options ("NVOs") to certain of the Company's employees in lieu of an element of cash remuneration for the financial year ended
Total share options in issue
Following the grant of Options, the Company has a total of 66,251,206 options to subscribe for new ordinary shares in the Company in issue, representing approximately 3.30% of the Company's current issued ordinary share capital.
"The issue of performance options at a significant premium to the current share price is designed to provide an appropriate incentive to achieve performance metrics and to deliver shareholder value, whilst the issue of nominal value options to employees in lieu of cash further strengthens alignment with shareholders whilst preserving the Company's cash resources."
The notifications below, made in accordance with the requirements of the Market Abuse Regulation, provide further details.
For further information please contact:
|
+44 (0)20 7031 7321 |
|
|
Nominated Adviser |
+44 (0)20 7220 0500 |
|
|
|
|
Joint Brokers |
+44 (0)20 7408 4090 |
|
|
|
+44 (0)20 3005 5000 |
Public & Investor Relations |
|
|
+44 (0) 20 7920 3150 |
|
+44 (0)7595 227750 +44 (0)7527 558846
|
The following notifications are intended to satisfy the Company's obligations under Article 19(3) of the Market Abuse Regulation.
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||||||
a) |
|
1. 2. 3.
|
||||||
2 |
Reason for notification |
|
||||||
a) |
Position/Status |
1 Chief Technical Officer 2. Chief Financial Officer 3. Chief Commercial Officer
|
||||||
|
Initial notification/amendment |
Initial notifications
|
||||||
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
a) |
|
|
||||||
b) |
LEI |
213800HN2ETG5476U328
|
||||||
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
|||||||
a) |
Description of the financial instrument, type of instrument and identification code |
Ordinary shares of
ISIN: GB00B11DDB67
|
||||||
b) |
Nature of transaction |
Awards of options to subscribe for new ordinary shares under the Quadrise Unapproved Share Option Plan 2016 and/or the Quadrise Enterprise Management Incentive Share Option Plan.
|
||||||
c) |
Price(s) and volume(s) |
|
||||||
d) |
Aggregated information |
n/a
|
||||||
e) |
Date of transaction |
|
||||||
f) |
Place of transaction |
Outside of a trading venue |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the